Compare Petróleo Brasileiro SA (PBR) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Petróleo Brasileiro SA vs State Street SPDR S&P Biotech ETF — how do they compare? Petróleo Brasileiro SA trades at $20.95 (market cap $130.37B), while State Street SPDR S&P Biotech ETF trades at $159.85. The key difference: Petróleo Brasileiro SA pays a 8.03% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| PBR | XBI | |
|---|---|---|
Market Cap | $130.37B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $22.03 | $169.55 |
52-Week Low | $11.54 | $93.43 |
Enterprise Value | $190.79B | — |
Dividend Yield | 8.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Petrobras (PBR) trades at $20.83, up 3.53% with strong technical momentum as moving averages signal bullish alignment. The company demonstrates robust fundamentals with a low P/E of 5.29 and impressive ROE of 30.77%, supported by recent earnings beats and record production. Recent regulatory approvals for Brazilian drilling and LNG export initiatives highlight growth potential.
Outlook remains positive with analyst consensus favoring Buy ratings (50%) and strong free cash flow generation. Key risks include oil price volatility and geopolitical factors in Brazil. The stock offers value with attractive valuation metrics and dividend yield, though investors should monitor execution of international expansion plans.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
